AZD2171 in Treating Patients With Progressive Locally Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2007 by National Cancer Institute (NCI).
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Princess Margaret Hospital, Canada
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00227760
First received: September 26, 2005
Last updated: September 5, 2012
Last verified: September 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | No date given |
| Estimated Primary Completion Date: | May 2013 (Final data collection date for primary outcome measure) |
Publications:
Sridhar SS, Mackenzie MJ, Hotte SJ, et al.: AZD2171 (cediranib) is active in first line metastatic renal cell carcinoma (RCC): interim results of a phase II trial. A trial of the PMH phase II Consortium. [Abstract] American Association for Cancer Research: Molecular Targets and Cancer Therapeutics, October 22-26, 2007, San Francisco, CA A-10, 2007.